CompletedPhase 2

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

United States201 participantsStarted 2023-08-28

Plain-language summary

The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 \[0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of bilateral primary open angle glaucoma or ocular hypertension Exclusion Criteria: * Closed or very narrow angles (Grades 0-1) or those the investigator judges as occludable and/or with evidence of peripheral anterior synechiae \>/= 180 degrees by gonioscopy within 6 months prior to screening visit in either eye Note: Other inclusion/exclusion criteria apply.

What they're measuring

Efficacy as Assessed by Change in Intraocular Pressure

Timeframe: Day 28

Trial details

NCT IDNCT05913232

SponsorD. Western Therapeutics Institute, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-08-29

Results submitted2025-08-08

View on ClinicalTrials.gov More Glaucoma Open-Angle Primary trials